InnoCare Pharma Ltd. Class A

As of June 30, 2024, InnoCare Pharma Ltd. Class A carries a market capitalization of 14.29B, placing it among publicly traded companies globally. Its enterprise value stands at 8.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

InnoCare Pharma Ltd. Class A's next confirmed earnings release is scheduled for October 26, 2026.

As of June 30, 2024, InnoCare Pharma Ltd. Class A has 1.76B shares outstanding.

These figures are as of June 30, 2024. The price-to-sales ratio is 18.35, and the price-to-book ratio stands at 2.07.

These figures are as of June 30, 2024. The EV/Sales ratio of 10.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 8.16B versus a market cap of 14.29B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2024, InnoCare Pharma Ltd. Class A maintains a current ratio of 3.82, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.00, indicating elevated leverage, while an interest coverage ratio of -25.97 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2024, InnoCare Pharma Ltd. Class A posted a negative return on equity (ROE) of -6.55, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.74, reflecting losses generated across the asset base. The company generates approximately 742,487.87 in revenue per employee across its workforce of 1,051.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.99 indicates how many times InnoCare Pharma Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2024, InnoCare Pharma Ltd. Class A recorded 1.46M in income tax expense. The company reported a pretax loss of -482.94M and -470.89M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, InnoCare Pharma Ltd. Class A's stock has gained approximately 11.90% over the past 52 weeks. The 50-day moving average sits at 29.01, while the 200-day moving average is 25.94.

Over the twelve months ended June 30, 2024, InnoCare Pharma Ltd. Class A generated 780.73M in revenue and converted that into -470.89M in net income, yielding earnings per share of -0.27. EBITDA reached -653.23M, while operating income came in at -642.19M.

As of June 30, 2024, InnoCare Pharma Ltd. Class A holds 7.55B in cash and equivalents against 1.39B in total debt, resulting in a net debt position of -5.59B. Total book value stands at 6.91B, with working capital of 5.96B providing operational flexibility.

These figures cover the twelve months ended June 30, 2024.

Over the twelve months ended June 30, 2024, InnoCare Pharma Ltd. Class A posted a gross margin of 85.59, reflecting its pricing power and cost economics. The operating margin of -82.26 and net profit margin of -60.31 provide insight into operational efficiency.

Over the twelve months ended June 30, 2024, InnoCare Pharma Ltd. Class A paid dividends of 0.00 per share. The dividend payout ratio of -0.06 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.23, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to InnoCare Pharma Ltd. Class A shareholders.

As of June 30, 2024, InnoCare Pharma Ltd. Class A has an Altman Z-Score of 2.96, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.